首站-论文投稿智能助手
典型文献
TMEM106A transcriptionally regulated by promoter methylation is involved in invasion and metastasis of hepatocellular carcinoma
文献摘要:
Expression of transmembrane protein 106A(TMEM106A)has been reported to be dysregulated in several types of cancers.However,the role of TMEM106A in hepatocellular carcinoma(HCC)is still unknown.In the present study,we demonstrate that TMEM106A is markedly downregulated in HCC compared with normal liver tissue.In parti-cular,tumor-specific DNA methylation of TMEM106A is frequently observed in tumor tissues from HCC patients.Immunohistochemistry and pyrosequencing reveal a significant relationship between TMEM106A methylation and downregulation of protein expression.Receiver operating characteristic(ROC)curve analysis reveals that methy-lation of TMEM106A in tumor samples is different from that in non-malignant adjacent tissues of HCC patients.Moreover,HCC patients with TMEM106A hypermethylation have a poor clinical prognosis.5-Aza-2'-deoxycytidin treatment of hypermethylated TMEM106A in highly metastatic HCC cells increases the expression of TMEM106A.Functional assays reveal that overexpression of TMEM106A significantly suppresses the malignant behavior of HCC cells in vitro and decreases tumorigenicity and lung metastasis in vivo.Mechanistically,TMEM106A inhibits epi-thelial mesenchymal transition(EMT)of HCC cells through inactivation of the Erk1/2/Slug signaling pathway.In conclusion,our findings demonstrate that TMEM106A is an inhibitor of HCC EMT and metastasis,and TMEM106A is often transcriptionally downregulated by promoter methylation,which results in reduced levels of TMEM106A protein and predicts poor survival outcomes for HCC patients.
文献关键词:
作者姓名:
Shiming Shi;Biao Wang;Jinglei Wan;Lina Song;Guiqi Zhu;Junxian Du;Luxi Ye;Qianqian Zhao;Jialiang Cai;Qing Chen;Kun Xiao;Jian He;Lei Yu;Zhi Dai
作者机构:
Liver Cancer Institute,Zhongshan Hospital,Fudan University&State Key Laboratory of Genetic Engineering,Fudan University,Shanghai 200032,China;Department of Radiation Oncology,Zhongshan Hospital,Fudan University,Shanghai 200032,China;Department of Pediatric Surgery,the First Affiliated Hospital of Sun Yat-sen University,Guangzhou 510080,China;Department of General Surgery,Zhongshan Hospital(South),Fudan University,Shanghai Public Health Clinical Center,Fudan University,Shanghai 200083,China;Department of Gastrointestinal Surgery,Shandong Provincial Hospital Affiliated to Shandong First Medical University,Jinan 250021,China;Department of Liver Surgery and Transplantation,Liver Cancer Institute,Zhongshan Hospital,Fudan University,Shanghai 200032,China
引用格式:
[1]Shiming Shi;Biao Wang;Jinglei Wan;Lina Song;Guiqi Zhu;Junxian Du;Luxi Ye;Qianqian Zhao;Jialiang Cai;Qing Chen;Kun Xiao;Jian He;Lei Yu;Zhi Dai-.TMEM106A transcriptionally regulated by promoter methylation is involved in invasion and metastasis of hepatocellular carcinoma)[J].生物化学与生物物理学报(英文版),2022(07):1008-1020
A类:
TMEM106A,106A,deoxycytidin
B类:
transcriptionally,by,promoter,involved,invasion,metastasis,hepatocellular,carcinoma,Expression,transmembrane,protein,has,been,reported,dysregulated,several,types,cancers,However,role,HCC,still,unknown,In,present,study,demonstrate,that,markedly,downregulated,compared,normal,liver,parti,cular,specific,frequently,observed,tissues,from,patients,Immunohistochemistry,pyrosequencing,relationship,between,downregulation,Receiver,operating,characteristic,curve,analysis,reveals,samples,different,malignant,adjacent,Moreover,hypermethylation,have,poor,clinical,prognosis,Aza,treatment,hypermethylated,highly,metastatic,cells,increases,Functional,assays,overexpression,significantly,suppresses,behavior,vitro,decreases,tumorigenicity,lung,vivo,Mechanistically,inhibits,epi,thelial,mesenchymal,transition,EMT,through,inactivation,Erk1,Slug,signaling,pathway,conclusion,our,findings,inhibitor,often,which,results,reduced,levels,predicts,survival,outcomes
AB值:
0.494362
相似文献
N6?methyladenosine modification of CENPK mRNA by ZC3H13 promotes cervical cancer stemness and chemoresistance
Xian Lin;Feng Wang;Jian Chen;Jing Liu;Yi?Bin Lin;Li Li;Chuan?Ben Chen;Qin Xu-Departments of Gynecology,Fujian Cancer Hospital and Fujian Medical University Cancer Hospital,Fujian Medical University,Fuzhou 350014,China;Department of Radiation Oncology,Fujian Cancer Hospital and Fujian Medical University Cancer Hospital,Fujian Medical University,Fuzhou 350014,China;Shenzhen Key Laboratory of Immunity and Inflammatory Diseases,Peking University Shenzhen Hospital,Shenzhen Peking University?the Hong Kong University of Science and Technology Medical Center,Shenzhen 518036,Guangdong,China;Outpatient Department,Fujian Hospital of People's Armed Police,Fujian Medical University,Fuzhou 350014,China
SNORA23 inhibits HCC tumorigenesis by impairing the 2?-O-ribose methylation level of 28S rRNA
Zhiyong Liu;Yanan Pang;Yin Jia;Qin Qin;Rui Wang;Wei Li;Jie Jing;Haidong Liu;Shanrong Liu-Department of Laboratory Diagnostics,Changhai Hospital,Second Military Medical University,Shanghai 200433,China;Department of Gastroenterology and Hepatology,Zhongshan Hospital,Fudan University,Shanghai 200032,China;Department of Gastroenterology,Changhai Hospital,Second Military Medical University,Shanghai 200433,China;Shanghai Institute of Pancreatic Diseases,Shanghai 200433,China;Department of Chemistry and State Key Laboratory of Molecular Engineering of Polymers,Fudan University,Shanghai 200433 China;Department of General Surgery,Changzheng Hospital,Second Military Medical University,Shanghai 200433,China;Shanghai Fourth People's Hospital,Tongji University School of Medicine,Shanghai 200081,China
Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
Leyi Yao;Qian Zhao;Ding Yan;Ziying Lei;Yali Hao;Jinghong Chen;Qian Xue;Xiaofen Li;Qingtian Huang;Daolin Tang;Q.Ping Dou;Xin Chen;Jinbao Liu-Affiliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,State Key Laboratory of Respiratory Disease,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;Institute of Digestive Disease of Guangzhou Medical University,The Sixth Affiliated Hospital of Guangzhou Medical University,Qingyuan People's Hospital,Qingyuan 511518,China;School of Public Health,Guangzhou Medical University,Guangzhou,511436,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
Hypoxia-inducible factor-2α and its missense mutations: potential role in HCC diagnosis, progression, and prognosis and underlying mechanism
Jun Li;Yibo Yan;Ganxin Wang;Zaozao Huang-Emergency Department,Liyuan Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430077,China;Division of Cardiology,Liyuan Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430077,China;Division of Oncology,Liyuan Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430077,China;Cancer Center,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China;Yangchunhu Community Hospital,Liyuan Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430077,China
Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer
Junru Feng;Hui Lu;Wenhao Ma;Wenjing Tian;Zhuan Lu;Hongying Yang;Yongping Cai;Pengfei Cai;Yuchen Sun;Zilong Zhou;Jiaqian Feng;Jiazhong Deng;Ying Shu;Kun Qu;Weidong Jia;Ping Gao;Huafeng Zhang-Anhui Key Laboratory of Hepatopancreatobiliary Surgery,Department of General Surgery,Anhui Provincial Hospital,The First Affiliated Hospital of USTC,Division of Life Science and Medicine,University of Science and Technology of China,Hefei 230027,China;Hefei National Laboratory for Physical Sciences at Microscale,The Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease,School of Basic Medical Sciences,Division of Life Science and Medicine,University of Science and Technology of China,Hefei 230027,China;Shenzhen People's Hospital,Second Clinical Medical College of Jinan University,First Affiliated Hospital of Southern University of Science and Technology,Shenzhen 518000,China;Department of Pathology,School of Medicine,Anhui Medical University,Hefei 230032,China;School of Medicine and Institutes for Life Sciences,South China University of Technology,Guangzhou 510006,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。